Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus first-line chemotherapy as adjuvant treatment for biomarker-selected stage III gastric cancer
ChiCTR1900027123Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric cancer (GC), sponsored by Renji Hospital. Primary endpoint: Relapse-free survival time. Started Dec 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1900027123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027123.